575504-30-2

Basic information

• Product Name: 1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI)
• Synonyms: 1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI);7-HYDROXY-6-METHYL-2,3-DIHYDRO-1H-INDENE-4-CARBALDEHYDE
• CAS NO: 575504-30-2
• Molecular Formula: C₁₁H₁₂O₂
• Molecular Weight: 176.214
• Product Categories: CYCLOHEXANE
• Mol File: 575504-30-2.mol

Chemical Properties

• Boiling Point: 325°C at 760 mmHg
• Flash Point: 137.9°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 0.000125mmHg at 25°C
• Refractive Index: 1.635
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI)(575504-30-2)
• EPA Substance Registry System: 1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI)(575504-30-2)

Safety Data

• Hazardous Substances Data: 575504-30-2(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI) is used as an intermediate in the synthesis of other organic compounds. Its specific properties and uses may vary depending on the intended application, but it is generally considered to be a versatile and valuable building block for organic synthesis.
Used in Pharmaceutical Industry:
1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI) is used as a key component in the production of pharmaceuticals. Its structure and reactivity make it suitable for a wide range of reactions and transformations, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI) is utilized as a precursor for the synthesis of various agrochemicals. Its unique chemical properties allow for the creation of effective and targeted pest control solutions.
Used in Fine Chemicals Production:
1H-Indene-4-carboxaldehyde,2,3-dihydro-7-hydroxy-6-methyl-(9CI) is also employed in the production of fine chemicals, where its versatility and reactivity are harnessed to create high-quality specialty chemicals for various applications.

InChI:InChI=1/C11H12O2/c1-7-5-8(6-12)9-3-2-4-10(9)11(7)13/h5-6,13H,2-4H2,1H3

Upstream product

• 95-48-7 ortho-cresol 
• 1641-41-4 4-indanol 
• 1092553-17-7 4-hydroxy-5-methyl-2,3-dihydro-1H-inden-1-one 
• 1092553-18-8 4-hydroxy-2,3-dihydro-1H-indene-5-carboxaldehyde 
• 140840-98-8 8-methyl-3,4-dihydrocoumarin 
• 1807-36-9 8-methylcoumarin 
• 824-42-0 2-methoxy-3-methylbenzaldehyde 
• 20294-31-9 5-methyl-2,3-dihydro-1H-inden-4-ol 
• 100-97-0 hexamethylenetetramine 

Downstream Products

• 1092553-16-6 7-Methoxy-6-methyl-indan-4-carboxaldehyde 
• 1092551-88-6 3-{4-[(7-hydroxy-6-methylindan-4-yl)methyl]-3,5-dimethyl-1H-pyrazol-1-yl}propionic acid 

Relevant articles and documents

METHODS OF PRODUCING PYRAZOLE COMPOUNDS

The present invention is directed to methods of producing substituted pyrazole based compounds through novel intermediates and unique processes for preparing such intermediates which enables synthesis of final product through commercially viable route of synthesis. The present invention is also directed to novel methods of producing substituted pyrazole based thyroid like compounds, and solid forms of 3-{4-[(7-hydroxy-6-methyl-indan-4-yl)methyl]-3,5-dimethyl-1H-pyrazol-1-yl}-propanoic acid, its pharmaceutical compositions, and methods of preparation thereof.

BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.

Novel Compounds

The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

NOVEL COMPOUNDS

The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3' R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF

The present invention provides a compound represented by general formula (I): . or pharmaceutically acceptable salts thereof, wherein W is O, S(O)m, CH2 and the like: R1 is halogen, lower alkyl, halo-lower alkyl, CN and th